Formulation and In-vitro Evaluation of Risedronate Effervescent Floating Tablets

Abstract

Risedronate, is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. In the present research work effervescent floating matrix formulation of Risedronate by using various hydrophilic polymers. Initially analytical method development was done for the drug molecule. Absorption maxima was determined based on that calibration curve was developed by using different concentrations. Gas generating agent sodium bicarbonate concentration was optimized. Then the formulation was developed by using different concentrations of polymers of various natural polymers. The formulation blend was subjected to various preformualation studies, flow properties and all the formulations were found to be good indicating that the powder blend has good flow properties. Among all the formulations the formulations prepared with Methocel K4 M  retarded the drug release up to 12 hours in the concentration of  75 mg (F3).The formulations prepared by using Methocel K15M were unable to produce desired drug release, they were unable to retard drug release up to 12 hours. The formulations prepared with Locust bean gum were also retarded the drug release for more than 12 hours. Hence they were not considered. The optimized formulation dissolution data was subjected to release kinetics, from the release kinetics data it was evident that the formulation followed zero order mechanism of drug release.